




# Claims

1. A process for the preparation of an aromatic azo-compound 4



or a salt thereof,

- 5 comprising the step of treating aromatic amino-compounds 5 and 6



with (i) hydrogen peroxide and acetic acid, followed by (ii) conc. sulphuric acid, to yield aromatic azo-compound 4 or a salt thereof, wherein

each m and each n is independently 0, 1, 2, 3, 4 or 5, and

- 10 each R<sup>1</sup> and each R<sup>2</sup> is independently an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group which may include one or more heteroatoms N, O or S in its carbon skeleton,  
-F, -Cl, -Br, -I, -CF<sub>3</sub>, -CCl<sub>3</sub>, -CBr<sub>3</sub>, -CI<sub>3</sub>, -OH, -SH, -NH<sub>2</sub>, -CN, -NO<sub>2</sub>, -COOH,  
-R<sup>3</sup>-O-R<sup>4</sup>, -R<sup>3</sup>-S-R<sup>4</sup>, -R<sup>3</sup>-SO-R<sup>4</sup>, -R<sup>3</sup>-SO<sub>2</sub>-R<sup>4</sup>, -R<sup>3</sup>-SO<sub>2</sub>-OR<sup>4</sup>, -R<sup>3</sup>O-SO<sub>2</sub>-R<sup>4</sup>,  
15 -R<sup>3</sup>-SO<sub>2</sub>-N(R<sup>4</sup>)<sub>2</sub>, -R<sup>3</sup>-NR<sup>4</sup>-SO<sub>2</sub>-R<sup>4</sup>, -R<sup>3</sup>O-SO<sub>2</sub>-OR<sup>4</sup>, -R<sup>3</sup>O-SO<sub>2</sub>-N(R<sup>4</sup>)<sub>2</sub>,  
-R<sup>3</sup>-NR<sup>4</sup>-SO<sub>2</sub>-OR<sup>4</sup>, -R<sup>3</sup>-NR<sup>4</sup>-SO<sub>2</sub>-N(R<sup>4</sup>)<sub>2</sub>, -R<sup>3</sup>-N(R<sup>4</sup>)<sub>2</sub>, -R<sup>3</sup>-N(R<sup>4</sup>)<sub>3</sub><sup>+</sup>, -R<sup>3</sup>-P(R<sup>4</sup>)<sub>2</sub>,  
-R<sup>3</sup>-Si(R<sup>4</sup>)<sub>3</sub>, -R<sup>3</sup>-CO-R<sup>4</sup>, -R<sup>3</sup>-CO-OR<sup>4</sup>, -R<sup>3</sup>O-CO-R<sup>4</sup>, -R<sup>3</sup>-CO-N(R<sup>4</sup>)<sub>2</sub>, -R<sup>3</sup>-NR<sup>4</sup>-CO-R<sup>4</sup>,  
-R<sup>3</sup>O-CO-OR<sup>4</sup>, -R<sup>3</sup>O-CO-N(R<sup>4</sup>)<sub>2</sub>, -R<sup>3</sup>-NR<sup>4</sup>-CO-OR<sup>4</sup>, -R<sup>3</sup>-NR<sup>4</sup>-CO-N(R<sup>4</sup>)<sub>2</sub>, -R<sup>3</sup>-CS-R<sup>4</sup>,  
-R<sup>3</sup>-CS-OR<sup>4</sup>, -R<sup>3</sup>O-CS-R<sup>4</sup>, -R<sup>3</sup>-CS-N(R<sup>4</sup>)<sub>2</sub>, -R<sup>3</sup>-NR<sup>4</sup>-CS-R<sup>4</sup>, -R<sup>3</sup>O-CS-OR<sup>4</sup>,  
20 -R<sup>3</sup>O-CS-N(R<sup>4</sup>)<sub>2</sub>, -R<sup>3</sup>-NR<sup>4</sup>-CS-OR<sup>4</sup> or -R<sup>3</sup>-NR<sup>4</sup>-CS-N(R<sup>4</sup>)<sub>2</sub>, all optionally protected,  
wherein


each -R<sup>3</sup>- is independently a chemical bond, a C<sub>1</sub>-C<sub>10</sub> alkylene, C<sub>1</sub>-C<sub>10</sub> alkenylene or C<sub>1</sub>-C<sub>10</sub> alkynylene group, and

- 25 each -R<sup>4</sup> is independently hydrogen, unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl or unsubstituted C<sub>6</sub>-C<sub>10</sub> aryl.


2. A process as claimed in claim 1, wherein the aromatic amino-compounds 5 and 6 are the same and together form a symmetric aromatic azo-compound 4.

3. A process as claimed in claim 1, wherein the aromatic amino-compounds 5 and 6 are different and together form an asymmetric aromatic azo-compound 4.


4. A process for the preparation of 3,3'-azo-bis(6-hydroxybenzoic acid) 1



or a salt or derivative thereof, comprising the step of treating a 5-amino salicylic acid derivative 2a



or a salt or derivative thereof, with (i) hydrogen peroxide and acetic acid, followed by (ii) conc. sulphuric acid, to yield a 3,3'-azo-bis(6-hydroxybenzoic acid derivative) 1a



or a salt or derivative thereof, wherein

X is OR, SR or N(R)<sub>2</sub>,

when X is OR or SR, R is independently an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group which may include one or more heteroatoms N, O or S in its carbon skeleton, hydrogen, -Si(alkyl)<sub>3</sub>, or -Sn(alkyl)<sub>3</sub>, and

when X is N(R)<sub>2</sub>, each R is independently an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group which may include one or more heteroatoms N, O or S in its carbon skeleton, hydrogen, -SO<sub>2</sub>-(aryl), -NH<sub>2</sub>, -NH(alkyl) or -NH(aryl), or both R  
5 together form an optionally substituted cycloheteroalkyl, cycloheteroalkenyl or heteroaryl group.

5. A process as claimed in claim 4, wherein X is OR and R is an optionally substituted alkyl, aryl or arylalkyl group.

10

6. A process as claimed in claim 5, wherein X is OR and R is an unsubstituted alkyl group.

7. A process as claimed in claim 6, wherein X is OR and R is an unsubstituted  
15 C<sub>1</sub>-C<sub>6</sub> alkyl group.


8. A process as claimed in claim 7, wherein X is OR and R is methyl.

9. A process as claimed in claim 5, wherein X is OR and R is an optionally  
20 substituted arylalkyl group.


10. A process as claimed in claim 9, wherein X is OR and R is benzyl.

11. A process as claimed in claim 4, further comprising a step of deprotecting  
25 the 3,3'-azo-bis(6-hydroxybenzoic acid derivative) 1a to yield 3,3'-azo-bis(6-hydroxybenzoic acid) 1 or a salt or other derivative thereof.

12. A process as claimed in claim 11, wherein X is OR, and a 3,3'-azo-bis(6-hydroxybenzoic acid ester) 1b




is deprotected with sodium hydroxide to yield the disodium salt **1d** of 3,3'-azo-bis(6-hydroxybenzoic acid)




5

13. A process as claimed in claim 12, wherein X is OR, both R are methyl, and a dimethyl-3,3'-azo-bis(6-hydroxybenzoate) **1c**



10 is deprotected with sodium hydroxide to yield the disodium salt **1d** of 3,3'-azo-bis(6-hydroxybenzoic acid)



15

14. 3,3'-Azo-bis(6-hydroxybenzoic acid) **1** or a salt or derivative thereof, obtained by a process as claimed in claim 4.

15. Disodium salt **1d** of 3,3'-azo-bis(6-hydroxybenzoic acid), obtained by a process as claimed in claim 4.

20 16. A pharmaceutical composition, comprising 3,3'-azo-bis(6-hydroxybenzoic acid) **1** or a salt or derivative thereof as claimed in claim 14 and a pharmaceutically acceptable carrier or diluent.

17. A method of treating an inflammatory disease, comprising administering a pharmaceutically effective amount of 3,3'-azo-bis(6-hydroxybenzoic acid) **1** or a salt or derivative thereof as claimed in claim 14, to a subject in need of such treatment.

5

18. A method as claimed in claim 17, wherein the inflammatory disease is ulcerative colitis.